Bruno Carneiro De Medeiros, MD
Hematology · Palo Alto
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 16
- 2 carriers
- Office
- 1
On the public record
- California licence: Delinquent
Offices
1 location
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
16 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Medeiros’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
16 of 16 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A96304 · Delinquent
Licence status: Delinquent · since 2006 · expires 2026-03-31 · Federal University of Parana Center of Health Sciences.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$1,977
Medicare paid this office $1,977 for 18 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit | 17 | $1,677 | $45 |
Who their Medicare patients are
18 Original Medicare patients in 2024. Average age 76 · Health risk score 2.96. Above the middle of the specialty; the typical hematology clinician is at 2.35.
Conditions among them: High blood pressure 72%.
The office billed $20,033, Medicare allowed $2,978 and paid $1,977; for 40 services of 3 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 18 | 40 | 76 | 2.96 | $20,033 | $1,977 |
| 2023 | 19 | 41 | 75 | 2.43 | $18,242 | $1,438 |
| 2022 | 23 | 56 | 73 | 2.66 | $27,587 | $2,844 |
| 2021 | 26 | 66 | 70 | 2.49 | $28,659 | $2,472 |
| 2020 | 36 | 98 | 71 | 2.90 | $28,497 | $3,538 |
| 2019 | 41 | 127 | 72 | 3.15 | $11,431 | $7,311 |
| 2018 | 106 | 478 | 73 | 3.84 | $110,845 | $39,285 |
| 2017 | 200 | 991 | 72 | 2.83 | $288,358 | $88,247 |
| 2016 | 191 | 791 | 71 | 2.61 | $234,015 | $68,617 |
| 2015 | 202 | 851 | 73 | 2.81 | $235,835 | $71,872 |
| 2014 | 240 | 1,166 | 72 | 2.62 | $320,662 | $97,751 |
| 2013 | 208 | 1,088 | 72 | 2.52 | $291,646 | $84,997 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Short return visit | 15 | $737 | $26 |
2022: 1 service
| Short return visit | 17 | $794 | $28 |
2021: 1 service
| Short return visit | 23 | $1,323 | $27 |
2020: 2 services
| Short return visit (20+ min) | 24 | $1,250 | $35 |
| Short return visit | 24 | $819 | $23 |
2019: 2 services
| Return visit (30+ min) | 20 | $3,142 | $67 |
| Short return visit (20+ min) | 36 | $2,322 | $38 |
2018: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $12,894 | $90 |
| Return visit (30+ min) | 47 | $8,428 | $61 |
| Long return visit (40+ min) | 33 | $5,589 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,840 | $167 |
| Hospital discharge day management, more than 30 minutes | 22 | $2,684 | $93 |
| Short return visit (20+ min) | 30 | $2,028 | $38 |
| New patient visit (60+ min) | 13 | $1,884 | $145 |
2017: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $33,901 | $93 |
| Return visit (30+ min) | 68 | $15,842 | $64 |
| Long return visit (40+ min) | 72 | $14,587 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 49 | $9,263 | $178 |
| New patient visit (60+ min) | 37 | $5,275 | $143 |
| Hospital discharge day management, more than 30 minutes | 39 | $4,222 | $98 |
| Short return visit (20+ min) | 30 | $2,128 | $40 |
2016: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 57 | $27,592 | $93 |
| Return visit (30+ min) | 63 | $15,603 | $67 |
| Long return visit (40+ min) | 51 | $6,775 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $6,390 | $178 |
| New patient visit (60+ min) | 36 | $4,767 | $132 |
| Hospital discharge day management, more than 30 minutes | 29 | $3,014 | $97 |
| Short return visit (20+ min) | 29 | $1,732 | $38 |
2015: 9 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 48 | $25,028 | $93 |
| Return visit (30+ min) | 70 | $20,543 | $66 |
| New patient visit (60+ min) | 46 | $6,730 | $146 |
| Long return visit (40+ min) | 44 | $5,660 | $96 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,612 | $181 |
| Short return visit (20+ min) | 36 | $2,344 | $36 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,760 | $98 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,585 | $122 |
| New patient visit (45+ min) | 12 | $1,256 | $105 |
2014: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $36,003 | $92 |
| Return visit (30+ min) | 91 | $26,906 | $67 |
| New patient visit (60+ min) | 54 | $7,872 | $146 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,734 | $180 |
| Long return visit (40+ min) | 50 | $5,825 | $95 |
| Short return visit (20+ min) | 58 | $4,496 | $41 |
| Hospital discharge day management, more than 30 minutes | 28 | $3,337 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,857 | $64 |
2013: 7 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 58 | $30,744 | $88 |
| Return visit (30+ min) | 71 | $22,193 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,557 | $171 |
| Short return visit (20+ min) | 75 | $6,524 | $38 |
| New patient visit (60+ min) | 44 | $5,886 | $134 |
| Long return visit (40+ min) | 43 | $5,046 | $93 |
| Hospital discharge day management, more than 30 minutes | 30 | $3,132 | $95 |
Medicaid work
$453 in 2018
Medicaid paid $453 for 14 billed services this clinician did in 2018, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $453 |
| 2018 | 14 | 1 | 13 | $453 |
Money from drug and device companies
$886 in 2019
A payment is not proof that care is biased.
| Celgene | Idhifa | $886 | 1 payment
|
See the published payment
| Celgene | Paid to speak or teach · 2019-01-03 | Idhifa | $886 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Celgene Corporation · A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered Ag-221 in Subjects With Advanced Hematologic Malignancies With An Idh2 Mutation (Ag-221-C-001) · 2019 | Their institution | $31,805 |
| Novartis Pharmaceuticals Corporation · Decitabine in Combination With Midostaurin for Elderly Patients With Flt3 Itd and Or Tkd Positive Aml · 2019 | Their institution | $8,090 |
| Astellas Pharma Global Development · Economic Burden of Illness Among Patients With Aml in the US A Retrospective Database Analysis · 2019 | This clinician | $5,200 |
| JAZZ PHARMACEUTICALS INC. · Cltr0310-301 - Phase III, Multicenter, Randomized, Trial of Cpx-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) Aml · 2020 | Their institution | $2,368 |
| F. Hoffmann-La Roche AG · Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Anti-Pd-L1 Antibody Administered in Combination With Hu5f9-G4 To Patients With Relapsed Andor Refractory Acute Myeloid Leukemia · 2022 | This clinician | $1,031 |
| Novartis Pharmaceuticals Corporation · A Phase III Randomized Double Blind Study of Induction Daunorubicin and Or Cytarabine and Consolidation High Dose Cytarabine Chemotherapy Plus Midostaurin Pkc412ind Number 101261 Or Placebo in Newly Diagnosed Patients Less Than 60 Years of Age With Flt3 M · 2020 | Their institution | $608 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1760420657
- Licence
- CA A96304, CA PENDINGCalifornia A96304: Delinquent · expires 2026-03-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-06-03
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 269 Campus Dr, Stanford, CA, 94305